Search

A recent study conducted at Amsterdam University Medical Centers focused on data mining to identify undiagnosed cases of Riboflavin transporter deficiency (RTD), an inborn error of riboflavin transport. The research aimed to detect patients with possible RTD by screening Electronic Health Records (EHR) of patients visiting the hospital between 2004 and 2021. While no new RTD patients were found in the study, the findings suggest that the prevalence of RTD may be low, and the likelihood of missing this diagnosis in a tertiary referral hospital is limited. The study highlights the importance of early detection and treatment of RTD to prevent progressive neurological symptoms. [Extracted from the article]

Researchers at the University of Michigan have reported data on hidden hearing loss in a Charcot-Marie-Tooth type 1a mouse model, a prevalent hereditary peripheral neuropathy in humans. The study suggests that mild disruptions of auditory nerve myelination can lead to hidden hearing loss, with implications for patients with CMT1A or other mild peripheral neuropathies. The findings may help in developing clinical tests for hidden hearing loss, which are currently lacking. [Extracted from the article]

The University College London (UCL) conducted a study on hearing loss in primary mitochondrial diseases, finding that auditory impairments are often present due to mitochondrial dysfunction. The research involved 72 adults with primary mitochondrial diseases and highlighted the impact of various pathogenic DNA variants on both cochlear and neural/central auditory functions. The study emphasized the need for personalized, genotype-specific auditory assessments and innovative rehabilitation strategies for individuals with central auditory dysfunctions related to mitochondrial mutations. [Extracted from the article]

A recent study from Leiden University Medical Center focused on neuroanatomical anomalies in children with a rare genetic disorder known as Labyrinthine Aplasia, Microtia, and Microdontia (LAMM) syndrome. The research highlighted the importance of understanding brainstem anatomy when placing auditory brainstem implants in children with this syndrome, emphasizing the need for a multidisciplinary approach and family support in treating rare deafness. The findings suggest that individualized treatment based on anatomical differences can lead to positive outcomes in auditory development for affected children. [Extracted from the article]

A recent study conducted at the University of Ottawa focused on the prognostic value of electrophysiological and MRI findings for pediatric cochlear implant outcomes. The research reviewed existing evidence on the relevance of electric compound action potential (eCAP), electric auditory brainstem response (eABR), and MRI results in predicting post-cochlear implant speech perception outcomes in children. While the studies supported the prognostic value of eABR and MRI, caution was advised due to the observational and retrospective design of the included studies and the heterogeneity of the population. The research was peer-reviewed and published in the American Journal of Audiology. [Extracted from the article]

A patent has been issued for materials and methods aimed at delivering nucleic acids to cochlear and vestibular cells, developed by inventors from Massachusetts Eye and Ear Infirmary. The patent focuses on addressing genetically-based hearing loss, particularly targeting inner ear cells using adeno-associated virus (AAV) containing an Anc80 capsid protein for efficient gene transfer. This innovative gene therapy approach aims to treat hearing disorders by delivering transgenes to inner ear cells, potentially restoring hearing function. The patent outlines specific AAV vectors and methods for delivering transgenes to inner ear cells, offering promising avenues for future research and clinical applications in the field of gene therapy for hearing loss. [Extracted from the article]

A recent study conducted at the All India Institute of Speech and Hearing explored the differences in auditory and non-auditory characteristics among individuals with congenital, early-onset, and late-onset auditory neuropathy spectrum disorder (ANSD). The study included 95 individuals diagnosed with ANSD, divided into three groups based on age of onset. The researchers found that there were significant differences in audiological characteristics, such as pure tone average, audiogram configuration, and speech thresholds, between the three groups. These differences may be due to variations in etiology, pathophysiology, site of lesion, or genetic variability, and further research is needed to explore these factors. [Extracted from the article]

A systematic review conducted by researchers at Al-Azhar University examined the outcomes of cochlear implantation in patients with auditory neuropathy spectrum disorder (ANSD) and different genetic variants. The study found that certain genetic mutations, such as OTOF, GJB2, ATPA3, and OPA1, were associated with improved cochlear implant outcomes. However, PJVK mutations were linked to worse outcomes, and TMPRSS3 mutations showed inconsistent results. The research suggests that early implantation may lead to better results in certain genetic variations. Overall, the study provides valuable information on the relationship between genetic variants and cochlear implant outcomes in ANSD patients. [Extracted from the article]

A recent study conducted by the Renal Research Institute explores a potential treatment for severe neonatal jaundice using allo-hemodialysis. Severe neonatal jaundice can lead to long-term neurological impairments or even death. The researchers developed a mathematical model to simulate the effects of allo-hemodialysis, where a neonate's blood is purified by flowing through a miniature hemodialyzer alongside the blood of a healthy adult. The model suggests that a single allo-hemodialysis session could effectively reduce neonatal bilirubin levels, potentially lowering the risks associated with severe neonatal jaundice. Further ex-vivo, animal, and clinical studies are needed to confirm these findings. [Extracted from the article]

A new report from Memorial Sloan-Kettering Cancer Center in New York City presents fresh data on the effects of intra-arterial carboplatin chemotherapy on the hearing of children with retinoblastoma. The study found that the administration of intra-arterial carboplatin did not cause hearing loss in any of the children evaluated. The researchers concluded that distortion product otoacoustic emission tests can be useful in monitoring children at risk of developing carboplatin ototoxicity. This research has been peer-reviewed and provides valuable information for healthcare professionals treating children with retinoblastoma. [Extracted from the article]

A new study conducted at Federal University Rio Grande do Norte examines the cortical activation pattern of a four-month-old infant with neurosyphilis using functional near-infrared spectroscopy (fNIRS). The study found delays in expressive language and broad motor skills in the infant, highlighting the importance of monitoring the development of babies with neurosyphilis. The research provides valuable insights into the effects of neurosyphilis on child development. [Extracted from the article]

Researchers at Washington University School of Medicine have conducted a study on hearing loss using cochlear implant electrodes to map the tonotopy of the human cochlea. The study aimed to assess the impact of sound intensity and the creation of an artificial "third window" on the tonotopic map. The findings showed a deviation from the traditional frequency-position map, particularly at high-intensity stimulations. The study suggests that understanding the influence of stimulus intensity on cochlear responses could improve cochlear implant programming and auditory rehabilitation. [Extracted from the article]

Sensorion, a biotechnology company specializing in hearing loss disorders, has announced positive clinical data from its gene therapy and small molecule programs at the World Congress of Audiology in Paris. The company presented new data on its gene therapy program, SENS-501, which aims to restore hearing in patients with otoferlin deficiency, a common form of congenital deafness. They also shared preliminary safety and efficacy data on their small molecule program, SENS-401, which is being tested for the prevention of hearing loss caused by cisplatin ototoxicity in patients undergoing chemotherapy. Additionally, the company reported significant effects on the preservation of residual hearing in patients treated with SENS-401 after cochlear implantation. [Extracted from the article]

Akouos Inc. has been granted a patent for their compositions and methods for treating non-age-associated hearing impairment in humans. The patent explains the complexity of the ear and the various factors that can cause hearing loss, including genetic and environmental factors. It also discusses the different patterns of inheritance for nonsyndromic deafness and the genes associated with this condition. The patent goes on to describe a composition involving nucleic acid vectors that can be used to treat non-syndromic sensorineural hearing loss. These vectors contain specific nucleotide sequences and coding regions of the otoferlin protein and can be encapsulated by AAV capsids, including the Anc80 capsid. The compositions can be formulated for intra-cochlear administration. Akouos Inc. is the assignee of the patent. [Extracted from the article]

A recent study conducted by researchers at the University of California San Francisco (UCSF) has identified a novel missense variant in the OPA3 gene that is associated with a family exhibiting congenital cataracts, sensorineural hearing loss, and neuropathy. This finding expands our understanding of OPA3-related disorders, as previous cases have primarily presented with optic atrophy. The study also highlights the different mechanisms of disease between missense variants and loss-of-function variants in the OPA3 gene. Optic atrophy is not always present in OPA3-related disorders, contrary to previous assumptions. [Extracted from the article]

This article discusses the origins of congenital deafness in mouse models of Waardenburg-Shah syndrome. The syndrome is caused by mutations in the human genes EDN3 and EDNRB, which result in hearing impairment. Previous explanations for auditory dysfunction focused on a deficiency in the migration of melanocytes to the inner ear. However, this study found that glial support of synapse assembly between auditory neurons and cochlear hair cells, as well as deficient synaptic transmission, played a role in hearing impairment. The research highlights the influence of genetic modifiers in auditory development and the separate roles of endothelin signaling in the neural crest and placode lineages. [Extracted from the article]

Akouos Inc. has been issued a patent for compositions and methods to treat non-age-associated hearing impairment in humans. The patent discusses the complexity of the ear and the various causes of hearing loss, including genetic and environmental factors. It also explores different inheritance patterns for nonsyndromic deafness and the genes associated with this condition. The invention involves using nucleic acid vectors to produce an active otoferlin protein in mammalian cells, potentially treating sensorineural hearing loss. The patent provides specific details about the vectors, including their nucleotide sequences, lengths, and encapsulation by AAV capsids. The compositions can be administered intracochlearly with a synthetic perilymph solution. The patent was filed by Hanan Al-Moyed and assigned to Akouos Inc. [Extracted from the article]

A recent study conducted by the University of Leuven (KU Leuven) provides new insights into Wolfram syndrome, a rare childhood disease characterized by diabetes mellitus, diabetes insipidus, blindness, deafness, neurodegeneration, and early death. The study focused on the role of oligodendroglia, a type of cell in the nervous system, in the development of optic neuropathy in Wolfram syndrome. The researchers found that oligodendroglia functions were largely preserved in mouse and patient-derived models of Wolfram syndrome, suggesting that the primary cause of the disease may lie elsewhere. Further investigation into neurons and neuron-oligodendroglia interactions is needed for potential future treatments. [Extracted from the article]

A recent study conducted at the Children's Hospital of Fudan University in Shanghai, China, explored the use of Chirp-auditory brainstem response (ABR) thresholds in assessing the hearing threshold of children diagnosed with auditory neuropathy spectrum disorder (ANSD) and sensorineural hearing loss (SNHL). The study included 20 children with ANSD, 31 children with SNHL, and 25 normal children as controls. The researchers found that Chirp-ABR thresholds were not suitable for predicting behavioral audiometry thresholds in ANSD children. They concluded that when there is a significant discrepancy (>30 dB) between Chirp-ABR thresholds and behavioral audiometry thresholds in hearing loss, ANSD should be highly suspected. [Extracted from the article]

A recent report from the Shandong Provincial ENT Hospital discusses research on Meniere's disease in adolescents. The study aimed to analyze the clinical features of adolescent Meniere's disease (MD) by retrospectively examining medical records, auditory and vestibular function tests, sensory organization tests, and imaging assessments. The findings showed that adolescents with MD had higher pure tone average thresholds, lower speech discrimination scores, and lower otoacoustic emission pass rates compared to patients with recurrent vertigo of childhood (RVC). Additionally, adolescents with bilateral MD exhibited worse performance in equilibrium score and strategy score compared to those with unilateral MD. The study concluded that adolescents with MD have similar vestibular information inputs as RVC, but their ability to maintain balance is worse. There may also be potential differences in vestibular weights between unilateral and bilateral MD, as well as potential effects on vision and proprioception. [Extracted from the article]

The article reports that a patent has been issued for a method using digital biomarkers to evaluate information processing speed, focusing on neurological assessments and cognitive impairment. Topics include the application of the method in drug research, diagnostics, and the use of mobile devices for assessing cognitive function.

A systematic review conducted by researchers at the University of Miami explores the relationship between diabetes mellitus (DM) and sensorineural hearing loss (SNHL) using preclinical animal models. The review found that hyperglycemia significantly affects auditory function and identified various pathological mechanisms contributing to DM-induced hearing impairment. The study also discussed potential therapeutic strategies for ameliorating DM-associated SNHL, including Asiaticoside, Trigonelline, Chlorogenic acid, and Huotanquyu granules. The researchers concluded that translating these findings to human studies could help effectively manage DM-associated co-morbidities such as hearing impairment. [Extracted from the article]

A recent study has found that hidden hearing loss (HHL), a condition characterized by normal audiometric thresholds but reduced sound-evoked cochlear compound action potentials, may be caused by mild disruptions of auditory nerve myelination. The study used a mouse model of Charcot-Marie-Tooth type 1A (CMT1A), a hereditary peripheral neuropathy, and found that these mice exhibited the functional hallmarks of HHL. The findings suggest that patients with CMT1A or other mild peripheral neuropathies are likely to suffer from HHL, and further research in this area may help develop clinical tests for HHL. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent study conducted at the Children's Hospital of Chongqing Medical University in China explored the relationship between modiolus density on high-resolution computed tomography (HRCT) and cochlear neurodysplasia (CND), a contributing factor to sensorineural hearing loss in children. The study analyzed HRCT images of 34 patients with unilateral neurological hearing loss and unilateral CND. Significant differences were observed in the CT values of the modiolus, width of cochlear nerve foramina, and width of internal auditory tract between the affected and healthy sides in patients with hearing loss. The study concluded that the elevated density of the modiolus on HRCT can be a valuable indicator for diagnosing CND. [Extracted from the article]

The article discusses a new clinical trial, which is investigating the impact of statins on reducing ototoxicity caused by platinum-based chemotherapy, specifically cisplatin. Topics include the high incidence of ototoxicity in chemotherapy patients, the potential protective effects of statins, and the need for further research to confirm these findings in human trials.

A patent application titled "Wireless Communication In An Implantable Medical Device System" has been published online. The application discusses the use of wireless technology in implantable medical device systems, which can provide therapeutic benefits to recipients. The inventors propose methods for generating and transmitting dynamic stimulation data wirelessly between components of the device system. The application also mentions the use of static configuration data to control the stimulation. The patent application provides detailed claims and technical information for further exploration. [Extracted from the article]

A systematic review conducted by researchers at Erasmus University Medical Center in Rotterdam, Netherlands, explores the use of the acoustic change complex (ACC) as a tool for assessing sound and speech discrimination capacity in children with hearing loss. The review found that ACC responses can be measured in infants and children, with evidence of age-dependency. The ACC method has potential clinical applications in measuring the neural capacity for sound discrimination in children with hearing loss, auditory neuropathy spectrum disorder (ANSD), and central auditory processing disorder (CAPD). However, the review also highlights the need for more efficient ACC test procedures for children and further research to investigate the relationship between objective ACC measures and behavioral measures of sound and speech perception. [Extracted from the article]

A patent application has been submitted for a method and composition that can enhance the effectiveness of stem cell therapies. The method involves administering a pharmaceutical composition containing an encapsulated cannabinoid compound to a subject before, during, or after the administration of stem cells. The treatment aims to reduce side effects and has shown a synergistic effect on the subject's condition. The patent application also includes a kit with instructions for administering the composition to subjects undergoing stem cell therapy. The invention involves administering a pharmaceutical composition containing encapsulated cannabinoid compounds, potentially in combination with terpene compounds derived from quillaja. The nanocapsules can be delivered through various methods, including vaporization and nebulization. The invention aims to improve the function of stem cells and reduce side effects associated with stem cell therapy. The patent application provides a detailed description of the methods and compositions, as well as a list of potential diseases and injuries that could benefit from this approach. [Extracted from the article]

A recent study conducted at Johns Hopkins University School of Medicine examined the relationship between Alzheimer's disease and hearing loss. The researchers used auditory brainstem responses (ABR) to screen for hearing loss in mice with a tauopathy, a condition associated with Alzheimer's disease. The study found that while the mice did not show accelerated hearing loss, they did exhibit mild central auditory dysfunction. These findings suggest that tauopathy may cause central auditory dysfunction even in the absence of overt hearing loss. The study was funded by the National Institute on Deafness And Other Communication Disorders and the National Institute on Aging. [Extracted from the article]

A recent study published in Science Translational Medicine has shown promising results in using a novel genome editing approach to restore hearing in adult mice with genetic deafness. The researchers targeted a specific mutation in the microRNA-96 (MiR-96) gene that causes progressive hearing loss in mice and humans. By using a CRISPR/Cas9 genome editing approach delivered through an adeno-associated virus (AAV), the researchers were able to disrupt the mutation and preserve auditory function in the mice. The study also found that the AAV-mediated genome editing approach had a good safety profile. This research offers hope for future clinical trials aimed at restoring auditory function in people with genetic forms of hearing impairment. [Extracted from the article]

A recent study conducted by Radboud University Medical Center in the Netherlands examined the long-term outcomes of cochlear implantation in individuals with Usher syndrome, a condition characterized by both hearing loss and retinitis pigmentosa. The study found that individuals with Usher syndrome benefited from cochlear implants in both the short-term and long-term. The study also highlighted the importance of early implantation for optimal outcomes, particularly in individuals with Usher syndrome type 1. Counseling for individuals with Usher syndrome type 2 and type 3 should emphasize the benefits of early implantation and encourage the use of hearing aids. [Extracted from the article]

Researchers at the University Hospital of Munich have published a report on otorhinolaryngology, specifically focusing on the rare case of a patient who had two electrical stimulators implanted in different cranial nerves. The patient, a 47-year-old with a trigeminus nerve stimulator and hearing problems, underwent cochlear implantation on the deaf side to improve hearing. The study also highlighted how the trigeminus stimulator affected the electrical stimulation in auditory evoked potentials measurement. This research provides valuable clinical considerations for using two different electrical stimulators in the same patient. [Extracted from the article]

Researchers from the University of Padova in Italy have conducted a review on the role of the Kir4.1 channel in auditory function and its impact on endocochlear potential and hearing loss. The Kir4.1 channel is a member of the inwardly rectifying potassium channel family and plays a crucial role in maintaining the electrical activity and potassium ion homeostasis of cells. Mutations in the Kir4.1 channel gene have been associated with various disorders, including EAST/SeSAME syndrome and Pendred syndrome. The researchers also found that the Kir4.1 channel can compensate for the deficiency of other potassium channels and maintain cochlear homeostasis. This research provides valuable insights into the mechanisms underlying hearing loss and potential therapeutic targets for its treatment. [Extracted from the article]

A recent study conducted by researchers at the University of Melbourne explores the use of diffusion-weighted magnetic resonance imaging (dMRI) in diagnosing and understanding auditory neuropathy. The study focuses on a case report of an adolescent with Riboflavin Transporter Deficiency (Type 2) who experienced a complete loss of functional hearing ability. The dMRI evaluation revealed significant changes in white-matter microstructure consistent with axonopathy, which may disrupt neural function in patients with auditory axonopathy. The study highlights the potential of dMRI technologies in identifying subtle changes in the auditory pathway and improving diagnostic tools for intervention. [Extracted from the article]

A recent report from Columbia University discusses the risk of sensorineural hearing loss in patients undergoing radiation therapy for brain, head, and neck tumors. The study highlights the importance of dose adjustments and multidisciplinary approaches to manage this potential side effect. Various interventions, such as hearing aids and cochlear implants, are available to address radiation-induced hearing loss. The research serves as a guide for radiation oncologists in understanding cochlear dosimetric considerations and managing adverse effects. [Extracted from the article]

A study conducted by researchers at Fudan University in Shanghai, China, has found that nuciferine, a natural active ingredient found in lotus species, can protect cochlear hair cells from ferroptosis, a form of programmed cell death. The study focused on the effects of nuciferine on cisplatin-induced ototoxicity, a side effect of the widely used antineoplastic drug cisplatin that causes hearing loss. The researchers discovered that nuciferine treatment reduced damage to hair cells and improved hearing function in a mouse model of acute cisplatin-induced hearing loss. These findings suggest that nuciferine could be a promising protective agent for treating cisplatin-induced hearing loss. [Extracted from the article]

A clinical trial conducted by Riphah International University in Pakistan is investigating the effects of different interventions on individuals with type 2 diabetes and peripheral neuropathy. The trial aims to compare the outcomes of patients who receive Action Observation Training or modified Otago exercises in addition to conventional treatment. The study is currently recruiting participants and is expected to be completed by September 15, 2024. Eligibility criteria include being diagnosed with type 2 diabetes for at least two years and being between the ages of 40 and 70. The primary contact for the study is Dr. Zeest Hashmi. [Extracted from the article]

A new report from researchers at Foundation Irccs Ist Neurology Carlo Besta in Milan, Italy provides details on a large cohort study of patients with myelin protein zero (MPZ)-related neuropathy. The study focused on five main mutation clusters across Italy and gathered clinical information on disease onset, severity, motor and sensory symptoms, and use of orthotics and aids. The research found that differentiating between childhood-onset demyelinating, late-onset axonal, and mild MPZ-related neuropathy is important for identifying different therapeutic targets. This study is the largest MPZ cohort ever collected and provides valuable insights into the clinical features and disease progression of these patients. [Extracted from the article]

A new report from Antwerp University Hospital in Belgium discusses the hearing outcomes of two cases of vestibular schwannoma, a type of tumor that affects the hearing nerve. The tumors were removed through surgery, and cochlear implantation was performed to restore hearing. The report describes the audiological outcomes, including speech understanding, sound localization, and phoneme discrimination, up to one year after surgery. This research provides valuable information for individuals with vestibular schwannoma who are considering cochlear implantation as a treatment option. [Extracted from the article]

A new report from the University of Rochester School of Medicine and Dentistry discusses the use of event-related potential (ERP) approaches to measure neural function in Rett Syndrome (RTT). The study found highly anomalous auditory evoked potentials (AEPs) in individuals with RTT, suggesting underlying neural dysfunction. However, the study also highlights the importance of considering response reliability at the single-trial level and the impact of non-neural noise sources on the estimation of processing deficits in RTT. The research concludes that denoising source separation techniques can help improve the accuracy of measuring neural dysfunction in RTT using ERP techniques. [Extracted from the article]

A systematic review of the literature on sciatic neuropathy was conducted by researchers at Stanford University. The study aimed to identify outcome measures that have been previously reported in studies on sciatic neuropathy. A total of 31 articles met the inclusion criteria and were analyzed. The most commonly reported outcome domain was pain. The study provides valuable information on the outcome measures used in sciatic neuropathy research. [Extracted from the article]

Akouos Inc. has been issued a patent for compositions and methods to treat non-age-associated hearing impairment in humans. The patent provides an overview of the complexity of the ear and the different disorders that can cause hearing loss. It explains the various types of hearing loss, including conductive and sensorineural, and discusses the genetic and environmental factors that can contribute to hearing impairment. The patent focuses on a specific type of hearing loss called non-syndromic sensorineural hearing loss and describes a composition and method for treating it. The invention involves using different nucleic acid vectors to generate a sequence that encodes an active otoferlin protein, which can help treat hearing loss in mammals. The patent also includes various embodiments and claims related to the composition and its components. [Extracted from the article]

A report from Clinica Universidad de Navarra in Pamplona, Spain, discusses the clinical profile, otologic, and auditory outcomes in patients with Down syndrome (DS). Down syndrome is the most common chromosomal disorder, and it often affects the head and neck area, leading to consultations with pediatric otolaryngologists or otologists. The study analyzed a sample of 16 pediatric patients with Down syndrome over the past 24 years and found that these patients have a predisposition to ear diseases with auditory repercussions, with variable evolution depending on the disease and the child's intrinsic characteristics. The research emphasizes the need for specialized care for these patients due to the anatomical characteristics of their ears. [Extracted from the article]

A recent study conducted at James Cook University Hospital in Middlesbrough, United Kingdom, examined the treatment outcomes of cochlear implantation in pediatric patients with Cockayne syndrome (CS) and bilateral sensorineural hearing loss. The study found that cochlear implantation led to notable improvements in auditory function and quality of life for these patients. The researchers concluded that cochlear implantation can be beneficial for CS patients, particularly those who are post-lingual or have better cognitive function. This study provides valuable insights into the potential benefits of cochlear implantation for individuals with CS. [Extracted from the article]

A recent study conducted by the University of Ottawa examined the predictors of cochlear implant outcomes in pediatric auditory neuropathy. The study included 66 children with cochlear implants, 22 of whom had auditory neuropathy spectrum disorder (ANSD) and 44 with sensorineural hearing loss (SNHL). The results showed that there was no significant difference in speech perception outcomes between the two groups. Factors such as a longer follow-up with cochlear implants, a lower age at cochlear implant activation, and the use of two cochlear implants were found to be predictive of optimal outcomes. This research suggests that children with ANSD can achieve similar speech perception outcomes as children with SNHL. [Extracted from the article]

A study conducted at Princess Nourah bint Abdulrahman University in Riyadh, Saudi Arabia, examined the impact of newborn hearing screening (NHS) on the timing of cochlear implantation (CI) in children with prelingual deafness. The study found that children who were screened for hearing loss through the NHS had significantly earlier ages at presentation to the CI committee and age at implantation compared to those who were not screened. However, the implementation of the NHS did not have a significant effect on the timing of the actual CI surgery. The researchers concluded that further research is needed to reduce hospital delays before surgery to increase the likelihood of early implantation in children. [Extracted from the article]

The clinical trial NCT06424262 is currently underway to test a new cochlear implant called CI622D. This implant slowly releases a drug called dexamethasone, which helps reduce inflammation after surgery. The study aims to determine if the dexamethasone-releasing implant provides additional benefits in terms of implant performance and hearing outcomes compared to the standard implant without dexamethasone. The trial is recruiting adults with sensorineural hearing loss and participants will undergo various tests and questionnaires to assess their hearing ability and overall health. The study is expected to be completed by May 2026 and is being conducted in Australia, France, Germany, and the United Kingdom. [Extracted from the article]

A recent study conducted at the University of Health Sciences Turkey focused on cochlear implantation in a patient with Primrose syndrome, a rare genetic condition characterized by physical deformities, sensorineural hearing loss, and metabolic disorders. The study found that the cochlear implantation procedure was successful, with no complications reported during or after the surgery. The researchers concluded that further investigation is needed to better understand the outcomes of cochlear implantation in patients with Primrose syndrome. This study provides valuable insights into the potential therapeutic approach for sensorineural hearing loss associated with this syndrome. [Extracted from the article]

A recent study conducted at the University Medical Center Utrecht in the Netherlands aimed to compare the costs and outcomes of day-case cochlear implantation versus inpatient cochlear implantation in adults. The study found that there were no significant differences in costs, complications, objective hearing outcomes, quality of life, or postoperative course between the two approaches. The researchers concluded that a day-case approach to cochlear implant surgery does not result in a statistically significant reduction of healthcare-related costs compared to an inpatient approach. This information may be useful for individuals considering cochlear implantation surgery and healthcare providers involved in decision-making processes. [Extracted from the article]

A recent study investigated the role of a protein called TMEM135 in hearing. The researchers used mice with a mutation in the Tmem135 gene and found that these mice experienced progressive sensorineural hearing loss. The mutation caused a severe loss of outer hair cells and spiral ganglion neurons in the cochlea, leading to profound hearing loss. The study suggests that TMEM135 is crucial for maintaining key cochlear cell types and normal sensory function in the aging cochlea. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]